Is Bioporto A/S halal to invest in?

According to Musaffa's Shariah screening methodology, Bioporto A/S (BIOPOR.CO) is currently classified as HALAL as of April 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Bioporto A/S a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Bioporto A/S using these criteria to determine its compliance status.

Can Muslims buy shares of Bioporto A/S?

Muslim investors may consider investing in Bioporto A/S if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Bioporto A/S classified as HALAL?

Musaffa determines the Shariah status of Bioporto A/S by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Bioporto A/S updated?

The Shariah compliance status of Bioporto A/S may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Bioporto A/S become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Bioporto A/S?

You can check the latest Shariah compliance status of Bioporto A/S on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Bioporto A/S BIOPOR.CO

Last Updated: May 13, 12:00 AM·CSE

BIOPOR.CO Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: April 30, 2025

Report Source: 2024 Annual Report

Bioporto A/S. Stock Analysis BIOPOR.CO

Denmark Health Care Micro Cap Report: 2024 Annual

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

Shariah Compliance Report

An extensive business and financial screening of the company which specifies why a stock is halal or haram!

Bioporto A/S BIOPOR.CO

HALAL

Bioporto A/S. Stock Analysis BIOPOR.CO

Shariah Compliance Report

Disclaimer